InvestorsHub Logo
Followers 1
Posts 49
Boards Moderated 0
Alias Born 01/28/2017

Re: None

Thursday, 03/09/2017 8:43:31 AM

Thursday, March 09, 2017 8:43:31 AM

Post# of 76662
This PR still didn't tell me what I wanted to hear. Anybody else happen to notice they STILL failed to mention anything about convertable debt?? The only mention of finances is this quote below and to me it looks like they put the interest of the company and company growth before shareholders (or wouldnt they have put shareholders first on the list?) And that sounds like more conversions and more dilution to me! They say they will continue the balance of paying down debt with a balance of revenues and "opportunities that might continue to accelerate the growth of revenues and profits" - aka CONVERSIONS!!! "Continue a balance" - aka "continue" conversions. If there wasn't going to be any more conversions don't you think they would have mentioned that? Seems to be the biggest shareholder concern and they still continue to not address it. If this company is so great why is it still trading so low? Conversions and dilution, thats why. It's still going down before its going up, read between the lines!

"The Company will continue to manage its finances in a manner that best serves the Company, Company growth, and shareholders. The Company will also continue a balance of paying down debt through revenues as business warrants relative to opportunities that might continue to accelerate the growth of revenues and profits."

Also, they mention a supposed name change but why didn't they mention the new name as they have in the past? Thats not very reassuring. Sounds like they aren't set on "Endo BioSciences" anymore. They haven't mentioned this supposed new name for nearly TWO MONTHS now. Sounds like they're doing what they've done in the past, indecisive. Just my opinion.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent UBQU News